Recent Updates on microRNA as Potential Biomarkers for Diagnosis of Gestational Diabetes Mellitus

Background/Aims: Screening for gestational diabetes mellitus (GDM) are currently done at 24 - 28 weeks of conception, missing out on the most vulnerable period organogenesis and thus preventing clinicians from starting treatments until late second or third trimester. MicroRNAs (miR) small non-coding RNA molecules that could aid in detecting predicting GDM through establishing a novel non-invasive prenatal testing (NIPT) tool. The objective this study was to summarize recent updates plasma microRNAs as diagnostic biomarkers. Methods: Between April June 2021, PubMed literature search undertaken review articles human miR associated with GDM. Animal studies papers written languages other than English were excluded. Only miRNAs used avoid coagulation biases. Results: A total 31 found significantly upregulated samples patients It mainly during 2nd 3rd trimester except miR-223 miR-23a 9 – 11 gestation. Conclusion: Though extensive prospective cohort required, should be considered promising develop successful NIPT tool because they earliest, first J MEDICINE 2022; 23: 146-150